Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease epidermolysis bullosa
Phenotype C0007137|squamous cell carcinoma
Sentences 9
PubMedID- 25506404 Polymeric nanoparticles to combat squamous cell carcinomas in patients with dystrophic epidermolysis bullosa.
PubMedID- 20586780 Background: tumour-specific expression of matrix metalloproteinase (mmp)-7 has been noted in cutaneous squamous cell carcinomas (sccs) in patients with recessive dystrophic epidermolysis bullosa (rdeb).
PubMedID- 26302137 This article summarizes recommendations reached following a systematic literature review and expert consensus on the diagnosis and management of cutaneous squamous cell carcinomas in people with epidermolysis bullosa.
PubMedID- 25022710 squamous cell carcinoma in a patient with dystrophic epidermolysis bullosa: a wound management strategy.
PubMedID- 22564523 Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa.
PubMedID- 19760773 While its most severe variant, dystrophic epidermolysis bullosa (deb) is associated with squamous cell carcinoma (scc), the development of extracutaneous neoplasms in ebs is extremely rare.
PubMedID- 25758658 Electrochemotherapy, a potential new treatment for the management of squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: report of three cases.
PubMedID- 24960768 Subcutaneous spreading squamous cell carcinoma in a patient with epidermolysis bullosa.
PubMedID- 23398414 Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma.

Page: 1